Crinetics Pharmaceuticals announced patient dosing has begun in a Phase 2 clinical trial evaluating paltusotine for treating chronic hypersecretion of cortisol in patients with Cushing’s disease, according to a press release issued by the global pharmaceutical company on August 3, 2026. The trial targets an endocrine disorder characterized by prolonged exposure to excess cortisol, addressing a significant medical need where current treatment options remain limited.
Phase 2 Clinical Trial Design for Paltusotine in Cushing’s Disease
The clinical trial is designed to evaluate the safety, tolerability, and efficacy of paltusotine in adult patients diagnosed with Cushing’s disease. According to Crinetics Pharmaceuticals, the study focuses on whether the oral, once-daily nonpeptide somatostatin receptor type 2 (SSTR2) agonist can effectively control cortisol levels in individuals suffering from endogenous Cushing’s syndrome driven by adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas.
Trial investigators are monitoring urinary free cortisol (UFC) levels alongside clinical symptom improvements over a multi-month treatment period. Because Cushing’s disease frequently leads to severe metabolic complications—including hypertension, type 2 diabetes, and weight gain—managing cortisol overproduction remains the primary therapeutic endpoint for the study.
Understanding Cushing’s Disease and SSTR2 Agonism
Cushing’s disease occurs when a benign tumor on the pituitary gland releases excessive amounts of ACTH, stimulating the adrenal glands to overproduce cortisol. Traditional interventions often involve surgical removal of the pituitary adenoma, but persistent or recurrent disease requires targeted medical therapy.
Paltusotine works by selectively binding to SSTR2 receptors located on pituitary corticotroph adenoma cells. According to preclinical and early clinical data from Crinetics Pharmaceuticals, this targeted activation inhibits ACTH secretion, subsequently lowering cortisol synthesis in the adrenal glands without requiring frequent injections common among older somatostatin analogs.
Clinical Development Timeline and Regulatory Status
The initiation of the Phase 2 trial marks a crucial advancement in Crinetics Pharmaceuticals’ broader endocrinology pipeline. Alongside its development for Cushing’s disease, paltusotine has been evaluated for acromegaly, another rare endocrine condition driven by excess growth hormone.
Data gathered from the ongoing Phase 2 trial will dictate the design and sample size for subsequent pivotal Phase 3 registration studies. Regulatory authorities continue to monitor the drug’s safety profile as patient enrollment progresses across clinical sites participating in the study.
Keep reading